According to a recent LinkedIn post from Orbis Medicines, the company has released the fourth edition of its “In the Loop” newsletter, focusing on developments in oral macrocycles and biologics. The post highlights analysis of the FDA approval of Icotyde, described as a first-of-its-kind oral psoriasis pill, and discusses what this may indicate for the broader future of oral macrocycle therapeutics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The newsletter, as outlined in the post, also examines the commercial potential of oral biologics, including a case study on an oral GLP-1 therapy and the implications for the approaching patent cliff facing established treatments. This emphasis suggests Orbis Medicines is positioning itself intellectually around next-generation oral modalities, which may appeal to investors tracking differentiated drug-discovery platforms and emerging small-molecule alternatives to injectable biologics.
By curating commentary on regulatory milestones and commercial dynamics, the post indicates that Orbis Medicines is engaging with themes central to valuation in biotech, such as market access for novel mechanisms and lifecycle management around expiring patents. While the LinkedIn content does not disclose specific pipeline assets or financial metrics, the focus areas could signal where the company sees future partnering, R&D prioritization, or competitive opportunity within drug discovery and oral therapeutics.